サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1259874

COPD (慢性閉塞性肺疾患) 市場の規模・動向・産業分析・予測 (2023～2032年)：薬剤タイプ・製品タイプ・地域別

Chronic Obstructive Pulmonary Disease Market Size, Trends, Industry Analysis Report, By Drug Type; By Product Type; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
COPD (慢性閉塞性肺疾患) 市場の規模・動向・産業分析・予測 (2023～2032年)：薬剤タイプ・製品タイプ・地域別
出版日: 2023年03月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のCOPD (慢性閉塞性肺疾患) の市場規模は、2032年には312億9,000万米ドルの規模に成長すると予測されています。

当レポートでは、世界のCOPD (慢性閉塞性肺疾患) の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のCOPD (慢性閉塞性肺疾患) 市場の洞察

  • 産業概要
  • 市場力学
    • 推進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
  • PESTEL分析
  • 産業動向
  • バリューチェーン分析
  • COVID-19：影響分析

第5章 世界のCOPD (慢性閉塞性肺疾患) 市場：薬剤タイプ別

  • 主な調査結果
  • ホスホジエステラーゼ-4阻害剤
  • 気管支拡張薬
    • 長時間作用型気管支拡張薬
    • 短時間作用型気管支拡張薬
  • メチルキサンチン
  • コルチコステロイド

第6章 世界のCOPD (慢性閉塞性肺疾患) 市場：製品タイプ別

  • 主な調査結果
  • 吸入器
    • ドライパウダー吸入器
    • 定量吸入器
    • ソフトミスト吸入器
  • ネブライザー
    • 超音波ネブライザー
    • ジェットネブライザー

第7章 世界のCOPD (慢性閉塞性肺疾患) 市場：地域別

  • 主な調査結果
  • 北米
  • 欧州
  • アジア太平洋
  • 中東およびアフリカ
  • ラテンアメリカ

第8章 競合情勢

  • 拡張・買収の分析
  • 提携/協力/合意/展示会

第9章 企業プロファイル

  • AstraZeneca
  • GlaxoSmithKline（UK）
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Pneuma Respiratory
  • Microlife Corporation
  • HELTMAN Medikal A.S
  • Promed Technology Co. Limited
  • Abbott Laboratories（US）
  • Kyowa Hakko Kirin
  • Mylan NV
  • Novartis AG
  • Orion Corporation
  • Sanofi
  • Circassia Pharmaceuticals（UK）Teva Pharmaceutical Industries Ltd
  • LepuMedical Technology（Beijing）Co
  • Verona Pharmaceuticals
図表

List of Tables

  • Table 1 Global Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 2 Global Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 3 Chronic Obstructive Pulmonary Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 5 North America: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 7 U.S.: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 9 Canada: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 11 Europe: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 12 UK: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 13 UK: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 14 France: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 15 France: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 17 Germany: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 19 Italy: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 21 Spain: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 25 Russia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 28 China: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 29 China: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 30 India: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 31 India: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 35 Japan: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 39 South Korea: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 45 UAE: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 47 Israel: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 49 South Africa: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 51 Latin America: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 53 Mexico: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 55 Brazil: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • Table 57 Argentina: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)

List of Figures

Figure 1 Global Chronic Obstructive Pulmonary Disease Market, 2019-2032 (USD Billion)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top-Down & Bottom-Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Product Type

Figure 7 Global Chronic Obstructive Pulmonary Disease Market, by Product Type, 2022 & 2032 (USD Billion)

Figure 8 Market by Drug Type

Figure 9 Global Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2022 & 2032 (USD Billion)

Figure 10 Chronic Obstructive Pulmonary Disease Market Assessment, By Geography, 2019-2032 (USD Billion)

Figure 11 Strategic Analysis - Chronic Obstructive Pulmonary Disease Market

目次
Product Code: PM1324

The chronic obstructive pulmonary disease market size is expected to reach USD 31.29 billion by 2032, according to a new study by Polaris Market Research. The report " Chronic Obstructive Pulmonary Disease Market Size, Trends, Industry Analysis Report, By Drug Type; By Product Type; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

A long-lasting inflammatory lung condition that impairs lung airflow is a chronic obstructive pulmonary disease (COPD). Wheezing, coughing, mucus production, and breathing problems are just signs and symptoms of PD. The two main types of COPD are chronic bronchitis and emphysema, and the four phases of chronic obstructive pulmonary disease (COPD) are mild to highly severe.

One significant reason anticipated to accelerate the growth and demand of the chronic obstructive pulmonary disease market is the increase in COPD cases among the global population. In addition, the young population's intake of alcohol and tobacco is increasing, and more people are becoming aware of COPD and its treatment. COPD could develop as a result of tobacco use. Around the world, there are more and more adults who are dependent on cigarettes. Workplace air pollution and other risk factors are both present. The WHO states that cigarette smoke exposure is the leading cause of COPD.

Smoking is the primary environmental risk factor for COPD, although other exposures to the environment, such as those to air pollution and biomass fuels, may also be involved. In addition to disclosures, host factors can put people at risk for COPD. Some are accelerated aging, improper lung development, and aberrant genetics.

For instance, In January 2022, a phase 4 trial comparing Yuperli (revefenacin) with Spiriva (tiotropium) was conducted to improve lung health in persons with COPD. Theravance Biopharma and Mylan (Viatris) worked together to create it. You can use a nebulizer to inhale this solution.

Chronic Obstructive Pulmonary Disease Market Report Highlights:

By drug type, bronchodilator segment is expected to increase over a forecast period due to increased cases of COPD and asthma.

Nebulizers segment is expected to grow rapidly in the market over the forecast period due to new technologies invented in nebulizers.

The need for cutting-edge medicines, the rise of the healthcare infrastructure, and more government funding are expected to positively impact the North American market and contribute to its expansion.

The major international participants include AstraZeneca, Orion Corporation, Novartis, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Mylan (Viatris), CHIESI Farmaceutici SpA and others.

Polaris Market Research has segmented chronic obstructive pulmonary disease market report based on drug type, product type, and region:

Chronic obstructive pulmonary disease, by Drug Type (Revenue - USD Billion, 2019-2032)

Phosphodiesterase-4 Inhibitor

Bronchodilators

Long-Acting Bronchodilators

Short-Acting Bronchodilators

Methylxanthines

Corticosteroids

Chronic obstructive pulmonary disease, by Product Type (Revenue - USD Billion, 2019-2032)

Inhalers

Dry Powders Inhalers

Metered-Dose Inhalers

Soft Mist Inhalers

Nebulizers

Ultrasonic Nebulizers

Jet Nebulizers

Chronic obstructive pulmonary disease, by Region (Revenue - USD Billion, 2019-2032)

North America

U.S.

Canada

Europe

Netherland

Spain

Russia

Italy

UK

France

Germany

Asia Pacific

Malaysia

Indonesia

Japan

China

India

South Korea

Latin America

Argentina

Mexico

Brazil

Middle East & Africa

Saudi Arabia

UAE

South Africa

Israel

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Chronic Obstructive Pulmonary Disease Market Insights

  • 4.1. Chronic Obstructive Pulmonary Disease Market - Industry Snapshot
  • 4.2. Chronic Obstructive Pulmonary Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased government and pharmaceutical sector spending on R&D
      • 4.2.1.2. Increase consumer awareness and introduce new products
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Introduction of a new product is the industry's greatest challenge
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Chronic Obstructive Pulmonary Disease Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Chronic Obstructive Pulmonary Disease Market, by Drug Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Chronic Obstructive Pulmonary Disease, by Drug Type, 2019-2032 (USD Billion)
  • 5.3. Phosphodiesterase-4 Inhibitors
    • 5.3.1. Global Chronic Obstructive Pulmonary Disease Market, by Phosphodiesterase-4 Inhibitors, by Region, 2019-2032 (USD Billion)
  • 5.4. Bronchodilators
    • 5.4.1. Global Chronic Obstructive Pulmonary Disease Market, by Bronchodilators, by Region, 2019-2032 (USD Billion)
    • 5.4.2. Long-Acting Bronchodilators
      • 5.4.2.1. Global Chronic Obstructive Pulmonary Disease Market, by Long-Acting Bronchodilators, by Region, 2019-2032 (USD Billion)
    • 5.4.3. Short-Acting Bronchodilators
      • 5.4.3.1. Global Chronic Obstructive Pulmonary Disease Market, by Short-Acting Bronchodilators, by Region, 2019-2032 (USD Billion)
  • 5.5. Methylxanthines
    • 5.5.1. Global Chronic Obstructive Pulmonary Disease Market, by Methylxanthines, by Region, 2019-2032 (USD Billion)
  • 5.6. Corticosteroids
    • 5.6.1. Global Chronic Obstructive Pulmonary Disease Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)

6. Global Chronic Obstructive Pulmonary Disease Market, by Product Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
  • 6.3. Inhalers
    • 6.3.1. Global Chronic Obstructive Pulmonary Disease Market, by Inhalers, by Region, 2019-2032 (USD Billion)
    • 6.3.2. Dry Powders Inhalers
      • 6.3.2.1. Global Chronic Obstructive Pulmonary Disease Market, by Dry Powders Inhalers, by Region, 2019-2032 (USD Billion)
    • 6.3.3. Metered-Dose Inhalers
      • 6.3.3.1. Global Chronic Obstructive Pulmonary Disease Market, by Metered-Dose Inhalers, by Region, 2019-2032 (USD Billion)
    • 6.3.4. Soft Mist Inhalers
      • 6.3.4.1. Global Chronic Obstructive Pulmonary Disease Market, by Soft Mist Inhalers, by Region, 2019-2032 (USD Billion)
  • 6.4. Nebulizers
    • 6.4.1. Global Chronic Obstructive Pulmonary Disease Market, by Nebulizers, by Region, 2019-2032 (USD Billion)
    • 6.4.2. Ultrasonic Nebulizers
      • 6.4.2.1. Global Chronic Obstructive Pulmonary Disease Market, by Ultrasonic Nebulizers, by Region, 2019-2032 (USD Billion)
    • 6.4.3. Jet Nebulizers
      • 6.4.3.1. Global Chronic Obstructive Pulmonary Disease Market, by Jet Nebulizers, by Region, 2019-2032 (USD Billion)

7. Global Chronic Obstructive Pulmonary Disease Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Chronic Obstructive Pulmonary Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Chronic Obstructive Pulmonary Disease Market - North America
    • 7.3.1. North America: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
    • 7.3.2. North America: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.3.3. Chronic Obstructive Pulmonary Disease Market - U.S.
      • 7.3.3.1. U.S.: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.3.4. Chronic Obstructive Pulmonary Disease Market - Canada
      • 7.3.4.1. Canada: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • 7.4. Chronic Obstructive Pulmonary Disease Market - Europe
    • 7.4.1. Europe: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.4.3. Chronic Obstructive Pulmonary Disease Market - UK
      • 7.4.3.1. UK: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.4.4. Chronic Obstructive Pulmonary Disease Market - France
      • 7.4.4.1. France: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.4.5. Chronic Obstructive Pulmonary Disease Market - Germany
      • 7.4.5.1. Germany: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.4.6. Chronic Obstructive Pulmonary Disease Market - Italy
      • 7.4.6.1. Italy: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.4.7. Chronic Obstructive Pulmonary Disease Market - Spain
      • 7.4.7.1. Spain: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.4.8. Chronic Obstructive Pulmonary Disease Market - Netherlands
      • 7.4.8.1. Netherlands: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.4.9. Chronic Obstructive Pulmonary Disease Market - Russia
      • 7.4.9.1. Russia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • 7.5. Chronic Obstructive Pulmonary Disease Market - Asia Pacific
    • 7.5.1. Asia Pacific: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.5.3. Chronic Obstructive Pulmonary Disease Market - China
      • 7.5.3.1. China: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.5.4. Chronic Obstructive Pulmonary Disease Market - India
      • 7.5.4.1. India: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.5.5. Chronic Obstructive Pulmonary Disease Market - Malaysia
      • 7.5.5.1. Malaysia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.5.6. Chronic Obstructive Pulmonary Disease Market - Japan
      • 7.5.6.1. Japan: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.5.7. Chronic Obstructive Pulmonary Disease Market - Indonesia
      • 7.5.7.1. Indonesia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.5.8. Chronic Obstructive Pulmonary Disease Market - South Korea
      • 7.5.8.1. South Korea: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • 7.6. Chronic Obstructive Pulmonary Disease Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.6.3. Chronic Obstructive Pulmonary Disease Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.6.4. Chronic Obstructive Pulmonary Disease Market - UAE
      • 7.6.4.1. UAE: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.6.5. Chronic Obstructive Pulmonary Disease Market - Israel
      • 7.6.5.1. Israel: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.6.6. Chronic Obstructive Pulmonary Disease Market - South Africa
      • 7.6.6.1. South Africa: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
  • 7.7. Chronic Obstructive Pulmonary Disease Market - Latin America
    • 7.7.1. Latin America: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.7.3. Chronic Obstructive Pulmonary Disease Market - Mexico
      • 7.7.3.1. Mexico: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.7.4. Chronic Obstructive Pulmonary Disease Market - Brazil
      • 7.7.4.1. Brazil: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)
    • 7.7.5. Chronic Obstructive Pulmonary Disease Market - Argentina
      • 7.7.5.1. Argentina: Chronic Obstructive Pulmonary Disease Market, by Product Type, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Chronic Obstructive Pulmonary Disease Market, by Drug Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AstraZeneca
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. GlaxoSmithKline (UK)
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Boehringer Ingelheim International GmbH
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. F. Hoffmann-La Roche Ltd
    • 9.4.1. Company Overview
    • 9.4.2. Financial PerDrug Typeance
    • 9.4.3. Drug Type Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Pneuma Respiratory
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Microlife Corporation
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. HELTMAN Medikal A.S
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Promed Technology Co. Limited
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Abbott Laboratories (US)
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Kyowa Hakko Kirin
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Mylan NV
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Novartis AG
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Orion Corporation
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Sanofi
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Circassia Pharmaceuticals (UK) Teva Pharmaceutical Industries Ltd
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. LepuMedical Technology (Beijing)Co
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Verona Pharmaceuticals
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development